VEZT, a Novel Putative Tumor Suppressor, Suppresses the Growth and Tumorigenicity of Gastric Cancer

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Miao, Ruizhen ^a   Guo, Xiaobo ^a   Zhi, Qiaoming ^b   Shi, Yulong ^a   Li, Leping ^a   Mao, Xuehui ^a   Zhang, Li ^a   Li, Chensheng ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 56; MEMBRANE PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR 19; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VEZATIN;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CARCINOGENICITY; CELL CYCLE PROGRESSION; CELL DIVISION; CELL GROWTH; CELL INVASION; CELL JUNCTION; CELL MIGRATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE TARGETING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; METHYLATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR INVASION; VEZT GENE;

AGED; AGED, 80 AND OVER; ANIMALS; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HELICOBACTER INFECTIONS; HUMANS; LYMPHATIC METASTASIS; MALE; MEMBRANE PROTEINS; MICE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884231206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074409     Document Type: Article

References (55)

1. Forman D, Burley VJ, (2006) Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20: 633-649. doi:10.1016/j.bpg.2006.04.008. PubMed: 16997150.
2. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784-789. doi:10.1056/NEJMoa001999. PubMed: 11556297.
3. Yang L, (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20. PubMed: 16440411.
4. Becker KF, Keller G, Hoefler H, (2000) The use of molecular biology in diagnosis and prognosis of gastric cancer. Surg Oncol 9: 5-11. doi:10.1016/S0960-7404(00)00016-5. PubMed: 11525306.
5. Kang GH, Lee S, Kim JS, Jung HY, (2003) Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Invest 83: 519-526. doi:10.1097/01.LAB.0000064704.53132.65. PubMed: 12695555.
6. Lee JH, Park SJ, Abraham SC, Seo JS, Nam JH, et al. (2004) Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene 23: 4646-4654. doi:10.1038/sj.onc.1207588. PubMed: 15064707.
7. Bahloul A, Simmler MC, Michel V, Leibovici M, Perfettini I, et al. (2009) Vezatin, an integral membrane protein of adherens junctions, is required for the sound resilience of cochlear hair cells. EMBO. Mol Med 1: 125-138.
8. Küssel-Andermann P, El-Amraoui A, Safieddine S, Nouaille S, Perfettini I, et al. (2000) Vezatin, a novel transmembrane protein, bridges myosin VIIA to the cadherin-catenins complex. EMBO J 19: 6020-6029. doi:10.1093/emboj/19.22.6020. PubMed: 11080149.
9. Hyenne V, Harf JC, Latz M, Maro B, Wolfrum U, et al. (2007) Vezatin, a ubiquitous protein of adherens cell-cell junctions, is exclusively expressed in germ cells in mouse testis. Reproduction 133: 563-574. doi:10.1530/REP-06-0271. PubMed: 17379651.
10. Hyenne V, Louvet-Vallée S, El-Amraoui A, Petit C, Maro B, et al. (2005) Vezatin, a protein associated to adherens junctions, is required for mouse blastocyst morphogenesis. Dev Biol 287: 180-191. doi:10.1016/j.ydbio.2005.09.004. PubMed: 16199027.
11. Hyenne V, Souilhol C, Cohen-Tannoudji M, Cereghini S, Petit C, et al. (2007) Conditional knockout reveals that zygotic vezatin-null mouse embryos die at implantation. Mech Dev 124: 449-462. doi:10.1016/j.mod.2007.03.004. PubMed: 17452094.
12. Danglot L, Freret T, Le Roux N, Narboux Nême N, Burgo A, et al. (2012) Vezatin is essential for dendritic spine morphogenesis and functional synaptic maturation. J Neurosci 32: 9007-9022. doi:10.1523/JNEUROSCI.3084-11.2012. PubMed: 22745500.
13. Guo X, Jing C, Li L, Zhang L, Shi Y, et al. (2011) Down-regulation of VEZT gene expression in human gastric cancer involves promoter methylation and miR-43c. Biochem Biophys Res Commun 404: 622-627. doi:10.1016/j.bbrc.2010.12.026. PubMed: 21156161.
14. Guo X, Guo L, Ji J, Zhang J, Zhang J, et al. (2010) miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun 398: 1-6. doi:10.1016/j.bbrc.2010.05.082. PubMed: 20510161.
15. Guo X, Liu W, Pan Y, Ni P, Ji J, et al. (2010) Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma. Oncogene 29: 3908-3920. doi:10.1038/onc.2010.143. PubMed: 20440264.
16. Guo XB, Jing CQ, Li LP, Zhang L, Shi YL, et al. (2011) Down-regulation of miR-622 in gastric cancer promotes cellular invasion and tumor metastasis by targeting ING1 gene. World J Gastroenterol 17: 1895-1902. PubMed: 21528065.
17. Jiang J, Liu W, Guo X, Zhang R, Zhi Q, et al. (2011) IRX1 influences peritoneal spreading and metastasis via inhibiting BDKRB2-dependent neovascularization on gastric cancer. Oncogene 30: 4498-4508. doi:10.1038/onc.2011.154. PubMed: 21602894.
18. Guo XB, Guo L, Zhi QM, Ji J, Jiang JL, et al. (2011) Helicobacter pylori induces promoter hypermethylation and downregulates gene expression of IRX1 transcription factor on human gastric mucosa. J Gastroenterol Hepatol 26: 1685-1690. doi:10.1111/j.1440-1746.2011.06808.x. PubMed: 21649733.
19. Mirshahi P, Rafii A, Vincent L, Berthaut A, Varin R, et al. (2009) Vasculogenic mimicry of acute leukemic bone marrow stromal cells. Leukemia 23: 1039-1048. doi:10.1038/leu.2009.10. PubMed: 19340002.
20. Ding SZ, Goldberg JB, Hatakeyama M, (2010) Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol 6: 851-862. doi:10.2217/fon.10.37. PubMed: 20465395.
21. Katayama Y, Takahashi M, Kuwayama H, (2009) Helicobacter pylori causes runx3 gene methylation and its loss of expression in gastric epithelial cells, which is mediated by nitric oxide produced by macrophages. Biochem Biophys Res Commun 388: 496-500. doi:10.1016/j.bbrc.2009.08.003. PubMed: 19665002.
22. Kitajima Y, Ohtaka K, Mitsuno M, Tanaka M, Sato S, et al. (2008) Helicobacter pylori infection is an independent risk factor for Runx3 methylation in gastric cancer. Oncol Rep 19: 197-202. PubMed: 18097595.
23. Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, et al. (2012) Epigenetic mechanisms in gastric cancer. Epigenomics 4: 279-294. doi:10.2217/epi.12.22. PubMed: 22690664.
24. Resende C, Thiel A, Machado JC, Ristimäki A, (2011) Gastric cancer: basic aspects. Helicobacter 16 (Suppl 1):: 38-44. doi:10.1111/j.1523-5378.2011.00879.x. PubMed: 21896084.
25. Telford JL, Covacci A, Ghiara P, Montecucco C, Rappuoli R, (1994) Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: potential new therapies and vaccines. Trends Biotechnol 12: 420-426. doi:10.1016/0167-7799(94)90031-0. PubMed: 7765388.
26. Thiel A, Ristimäki A, (2012) Gastric cancer: basic aspects. Helicobacter 17 (Suppl 1):: 26-29. doi:10.1111/j.1523-5378.2012.00979.x. PubMed: 22958152.
27. Ushijima T, Nakajima T, Maekita T, (2006) DNA methylation as a marker for the past and future. J Gastroenterol 41: 401-407. doi:10.1007/s00535-006-1846-6. PubMed: 16799880.
28. Choi IS, Wu TT, (2005) Epigenetic alterations in gastric carcinogenesis. Cell Res 15: 247-254. doi:10.1038/sj.cr.7290293. PubMed: 15857579.
29. Esteller M, (2007) Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 16: R50-59. PubMed: 17613547.
30. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG, (2002) DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 111: 115-127. doi:10.1007/s00439-002-0783-6. PubMed: 12189484.
31. Jones PA, (2003) Epigenetics in carcinogenesis and cancer prevention. Ann N Y Acad Sci 983: 213-219. doi:10.1111/j.1749-6632.2003.tb05976.x. PubMed: 12724226.
32. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ, (1999) Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 94: 2373-2379. doi:10.1111/j.1572-0241.1999.01360.x. PubMed: 10483994.
33. Tsuji S, Tsujii M, Murata H, Nishida T, Komori M, et al. (2006) Helicobacter pylori eradication to prevent gastric cancer: underlying molecular and cellular mechanisms. World J Gastroenterol 12: 1671-1680. PubMed: 16586533.
34. Graham DY, Lew GM, Klein PD, Evans DG, Evans DJ Jr., et al. (1992) Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 116: 705-708. doi:10.7326/0003-4819-116-9-705. PubMed: 1558340.
35. Liu ZF, Chen CY, Tang W, Zhang JY, Gong YQ, et al. (2006) Gene-expression profiles in gastric epithelial cells stimulated with spiral and coccoid Helicobacter pylori. J Med Microbiol 55: 1009-1015. doi:10.1099/jmm.0.46456-0. PubMed: 16849720.
36. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, et al. (1991) Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325: 1132-1136. doi:10.1056/NEJM199110173251604. PubMed: 1891021.
37. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, et al. (1991) Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 325: 1127-1131. doi:10.1056/NEJM199110173251603. PubMed: 1891020.
38. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, et al. (2006) High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12: 989-995. doi:10.1158/1078-0432.CCR-05-2096. PubMed: 16467114.
39. Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, et al. (2003) Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 52: 502-506. doi:10.1136/gut.52.4.502. PubMed: 12631658.
40. Dong CX, Deng DJ, Pan KF, Zhang L, Zhang Y, et al. (2009) Promoter methylation of p16 associated with Helicobacter pylori infection in precancerous gastric lesions: a population-based study. Int J Cancer 124: 434-439. doi:10.1002/ijc.23891. PubMed: 18821580.
41. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, et al. (2009) Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma. Eur J Med Res 14: 453-458. PubMed: 19748854.
42. Luo D, Zhang B, Lv L, Xiang S, Liu Y, et al. (2006) Methylation of CpG islands of p16 associated with progression of primary gastric carcinomas. Lab Invest 86: 591-598. PubMed: 16534497.
43. Peterson AJ, Menheniott TR, O'Connor L, Walduck AK, Fox JG, et al. (2010) Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans. Gastroenterology 139: 2005-2017. doi:10.1053/j.gastro.2010.08.043. PubMed: 20801119.
44. Duggan DJ, Bittner M, Chen Y, Meltzer P, Trent JM, (1999) Expression profiling using cDNA microarrays. Nat Genet 21: 10-14. doi:10.1038/4434. PubMed: 9915494.
45. Perez-Diez A, Morgun A, Shulzhenko N, (2007) Microarrays for cancer diagnosis and classification. Adv Exp Med Biol 593: 74-85. doi:10.1007/978-0-387-39978-2_8. PubMed: 17265718.
46. Quackenbush J, (2006) Microarray analysis and tumor classification. N Engl J Med 354: 2463-2472. doi:10.1056/NEJMra042342. PubMed: 16760446.
47. Yang L, Xu L, (2012) GPR56 in cancer progression: current status and future perspective. Future Oncol 8: 431-440. doi:10.2217/fon.12.27. PubMed: 22515446.
48. Xu L, (2010) GPR56 interacts with extracellular matrix and regulates cancer progression. Adv Exp Med Biol 706: 98-108. doi:10.1007/978-1-4419-7913-1_8. PubMed: 21618829.
49. Xu L, Begum S, Barry M, Crowley D, Yang L, et al. (2010) GPR56 plays varying roles in endogenous cancer progression. Clin Exp Metastasis 27: 241-249. doi:10.1007/s10585-010-9322-3. PubMed: 20333450.
50. Block J, Breitsprecher D, Kühn S, Winterhoff M, Kage F, et al. (2012) FMNL2 drives actin-based protrusion and migration downstream of Cdc42. Curr Biol 22: 1005-1012. doi:10.1016/j.cub.2012.03.064. PubMed: 22608513.
51. Chemin K, Bohineust A, Dogniaux S, Tourret M, Guégan S, et al. (2012) Cytokine secretion by CD4+ T cells at the immunological synapse requires Cdc42-dependent local actin remodeling but not microtubule organizing center polarity. J Immunol 189: 2159-2168. doi:10.4049/jimmunol.1200156. PubMed: 22821962.
52. Elbediwy A, Zihni C, Terry SJ, Clark P, Matter K, et al. (2012) Epithelial junction formation requires confinement of Cdc42 activity by a novel SH3BP1 complex. J Cell Biol 198: 677-693. doi:10.1083/jcb.201202094. PubMed: 22891260.
53. Ku DH, Chang CD, Koniecki J, Cannizzaro LA, Boghosian-Sell L, et al. (1991) A new growth-regulated complementary DNA with the sequence of a putative trans-activating factor. Cell Growth Differ 2: 179-186. PubMed: 1868030.
54. Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, et al. (2001) The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Res 61: 8820-8829. PubMed: 11751404.
55. Koon HB, Ippolito GC, Banham AH, Tucker PW, (2007) FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets 11: 955-965. doi:10.1517/14728222.11.7.955. PubMed: 17614763.